Streetbeat News

Products Services

NVO

The term 'AI' has been named the word of the year for 2023 by Collins Dictionary, reflecting the rise and impact of artificial intelligence. The dictionary defines AI as 'the modelling of human mental functionality by computer programs'. The AI-powered language model has been much talked about in 2023, with examples of its use including helping make presentations and creating recipes. The dictionary also highlighted other trending words, including 'debanking', 'deinfluencing', and 'greedflation'.

Portfolio Pulse from Chris Katje

November 01, 2023 | 6:47 pm

EYPT

EyePoint Pharmaceuticals reported Q3 revenues of $15.20 million, up from $10 million a year ago, beating the $7.52 million consensus. The company reported a smaller-than-expected EPS loss of 33 cents, beating the consensus loss of 51 cents. The company's cash runway extends into 2025. EyePoint also announced interim masked safety data for its lead product candidate EYP-1901. The company's plans to initiate the VERONA Phase 2 clinical trial evaluating EYP-1901 in diabetic macular edema (DME) in the first quarter of 2024 remain on track. EYPT shares are up 17.20% at $7.06.

Portfolio Pulse from Vandana Singh

November 01, 2023 | 6:36 pm

VWAGY

Volkswagen AG (OTC:VWAGY) has reportedly postponed its decision to select a new location for its fourth gigafactory dedicated to electric vehicle (EV) battery production due to slower-than-expected uptake of EVs in the European market. The company has already selected sites in Germany, Spain, and Canada. The Czech Republic, a contender for the new factory, is opening up its proposed location to other investors due to the delay.

Portfolio Pulse from Shivani Kumaresan

November 01, 2023 | 6:29 pm

NSPR

InspireMD, Inc. (NASDAQ:NSPR) presented 30-day results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial at the Vascular InterVentional Advances (VIVA) meeting. The trial evaluated the safety and efficacy of the CGuard™ Carotid Stent System. The follow-up data supports the safety of the C-Guard EPS stent, with a low rate of major adverse events observed through 30 days. InspireMD anticipates reporting primary endpoint results from C-GUARDIANS in the second half of 2024 that may support a Premarket Approval (PMA) application.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 6:26 pm

TGTX

TG Therapeutics reported Q3 FY23 Briumvi sales of $25.1 million, up from $16 million in Q2 FY23. Total net product revenue since launch is approximately $48.9 million. Overall revenues reached $165.8 million, including a license revenue of $140 million from Neuraxpharm. The company reported a Q3 EPS of 73 cents compared to a loss of 26 cents a year ago. The FDA approved Briumvi in January 2023 for relapsing forms of multiple sclerosis. The company's cash position stood at $229.2 million. TGTX shares were up 31.5% at $10.16.

Portfolio Pulse from Vandana Singh

November 01, 2023 | 6:11 pm

MRK

The FDA has approved Merck & Co Inc's cancer drug, Keytruda, for use in treating locally advanced unresectable or metastatic biliary tract cancer (BTC). The approval was based on results from the Phase 3 KEYNOTE-966 trial, which showed a significant improvement in overall survival rates. This marks the sixth indication for Keytruda in gastrointestinal cancers. Merck also released data from the Phase 3 KEYNOTE-564 trial evaluating Keytruda for certain patients with renal cell carcinoma.

Portfolio Pulse from Vandana Singh

November 01, 2023 | 5:51 pm

AMD

INTC

QCOM

Advanced Micro Devices (AMD), Intel Corporation (INTC), and Qualcomm Incorporated (QCOM) have all reported positive developments, suggesting a recovery in the chip industry. AMD's Q3 results exceeded expectations, but a weaker-than-expected outlook led to a 2% drop in pre-market trading. Intel's Q3 report topped profit and revenue estimates, showing the PC market is rebounding. Qualcomm unveiled new PC laptop chips with AI features for 2024, aiming to challenge Apple Inc (AAPL) and boost Microsoft Corporation's (MSFT) AI rise.

Portfolio Pulse from Upwallstreet

November 01, 2023 | 5:49 pm

MNPR

Monopar Therapeutics Inc (NASDAQ:MNPR) is presenting data from its ongoing Phase 1b trial of camsirubicin in patients with advanced soft tissue sarcoma at the CTOS Annual Meeting. The trial has enrolled 14 patients, with 9 showing stable disease after treatment. All patients in the fourth and fifth cohorts achieved stable disease, with some experiencing a ~20% tumor size reduction. No dose-limiting toxicity has been observed. The company's shares are up 50.90% at $0.65.

Portfolio Pulse from Vandana Singh

November 01, 2023 | 5:22 pm

CLGN

CollPlant Biotechnologies has been granted a patent by the U.S. Patent and Trademark Office for its photocurable dermal filler product candidate, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 5:03 pm